Literature DB >> 27235620

Pharmacotherapy for Substance Use Disorders.

Jared Wilson Klein1.   

Abstract

This article reviews the current pharmacotherapy options available for the treatment of patients with substance use disorders. In the United States there are medications available to treat tobacco use disorders (nicotine replacement, bupropion, and varenicline), alcohol use disorders (naltrexone and acamprosate), and opioid use disorders (methadone and buprenorphine). These medications are likely underused and physicians should more readily prescribe for eligible patients.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Buprenorphine; Methadone; Naltrexone; Substance use disorder; Varenicline

Mesh：

Substances：

Year:  2016        PMID： 27235620     DOI： 10.1016/j.mcna.2016.03.011

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN： 0025-7125            Impact factor:   5.456


  14 in total

1.  Offering Emergency Buprenorphine Without a Prescription.

Authors:  Payel Jhoom Roy; Michael D Stein
Journal:  JAMA       Date:  2019-07-08       Impact factor: 56.272

Review 2.  The role of glucagon-like peptide 1 (GLP-1) in addictive disorders.

Authors:  Mette Kruse Klausen; Morgane Thomsen; Gitta Wortwein; Anders Fink-Jensen
Journal:  Br J Pharmacol       Date:  2022-02       Impact factor: 9.473

3.  The Role of Opiates in Social Pain and Suicidal Behavior.

Authors:  Benedicte Nobile; Pierre-Eric Lutz; Emilie Olie; Philippe Courtet
Journal:  Curr Top Behav Neurosci       Date:  2020

Review 4.  Potential uses of naltrexone in emergency department patients with opioid use disorder.

Authors:  Evan Stuart Bradley; David Liss; Stephanie Pepper Carreiro; David Eric Brush; Kavita Babu
Journal:  Clin Toxicol (Phila)       Date:  2019-03-04       Impact factor: 4.467

5.  Sophora alopecuroides L. var. alopecuroides alleviates morphine withdrawal syndrome in mice: involvement of alkaloid fraction and matrine.

Authors:  Saeed Kianbakht; Fataneh Hashem Dabaghian
Journal:  Iran J Basic Med Sci       Date:  2016-10       Impact factor: 2.699

6.  Naltrexone treatment for prolonged grief disorder: study protocol for a randomized, triple-blinded, placebo-controlled trial.

Authors:  James Gang; James Kocsis; Jonathan Avery; Paul K Maciejewski; Holly G Prigerson
Journal:  Trials       Date:  2021-02-01       Impact factor: 2.279

Review 7.  Intranasal Insulin: a Treatment Strategy for Addiction.

Authors:  Bhavani Kashyap; Leah R Hanson; William H Frey Ii
Journal:  Neurotherapeutics       Date:  2020-01       Impact factor: 7.620

8.  Exercise Training Mitigates Water Pipe Smoke Exposure-Induced Pulmonary Impairment via Inhibiting NF-κB and Activating Nrf2 Signalling Pathways.

Authors:  Abderrahim Nemmar; Suhail Al-Salam; Priya Yuvaraju; Sumaya Beegam; Badreldin H Ali
Journal:  Oxid Med Cell Longev       Date:  2018-03-06       Impact factor: 6.543

9.  Attenuation of Morphine Withdrawal Syndrome by Prosopis Farcta Extract and Its Bioactive Component Luteolin in Comparison with Clonidine in Rats.

Authors:  Ardeshir Moayeri; Maryam Azimi; Elahe Karimi; Ali Aidy; Naser Abbasi
Journal:  Med Sci Monit Basic Res       Date:  2018-10-09

10.  Influence of n-acetylcysteine maintenance on the pharmacodynamic effects of oral ethanol.

Authors:  William W Stoops; Justin C Strickland; Lon R Hays; Abner O Rayapati; Joshua A Lile; Craig R Rush
Journal:  Pharmacol Biochem Behav       Date:  2020-09-04       Impact factor: 3.533
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.